These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 17653836)

  • 21. The impact of lag time on the estimation of pharmacokinetic parameters. I. One-compartment open model.
    Nerella NG; Block LH; Noonan PK
    Pharm Res; 1993 Jul; 10(7):1031-6. PubMed ID: 8104333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pharmacokinetic model for analysis of drug disposition profiles undergoing enterohepatic circulation.
    Wajima T; Yano Y; Oguma T
    J Pharm Pharmacol; 2002 Jul; 54(7):929-34. PubMed ID: 12162711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetic analysis of pegylated human erythropoietin in rats.
    Jolling K; Ruixo JJ; Hemeryck A; Piotrovskij V; Greway T
    J Pharm Sci; 2004 Dec; 93(12):3027-38. PubMed ID: 15503315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A two-dimensional mathematical model of non-linear dual-sorption of percutaneous drug absorption.
    George K
    Biomed Eng Online; 2005 Jul; 4():40. PubMed ID: 15992411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients.
    Ait-Oudhia S; Vermeulen A; Krzyzanski W
    Biopharm Drug Dispos; 2011 Jan; 32(1):1-15. PubMed ID: 21162115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
    Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
    Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies.
    Hu S; Dunlavey M; Guzy S; Teuscher N
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):285-308. PubMed ID: 29368268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A transit compartment model unmasks OxyContin's reflective pharmacokinetics from urine measurements in humans.
    Linares OA; Schiesser WE; Linares AD; Stefanovski D; Boston RC
    J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):96-108. PubMed ID: 24813654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetic model of human insulin following different routes of administration.
    Potocka E; Baughman RA; Derendorf H
    J Clin Pharmacol; 2011 Jul; 51(7):1015-24. PubMed ID: 20940337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
    Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
    J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
    Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P
    Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
    Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
    J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a population pharmacokinetic model to describe olmesartan medoxomil/ hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects.
    Chae JW; Baek IH; Seo JW; Jung SH; Back HM; Song BJ; Lee BY; Yun HY; Kang W; Kwon KI
    Int J Clin Pharmacol Ther; 2014 Aug; 52(8):676-83. PubMed ID: 24849193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam.
    Hossain M; Wright E; Baweja R; Ludden T; Miller R
    Pharm Res; 1997 Mar; 14(3):309-15. PubMed ID: 9098872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population Pharmacokinetic and Exposure-dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients.
    Cosson V; Schaedeli-Stark F; Arab-Alameddine M; Chavanne C; Guerini E; Derks M; Mallalieu NL
    Clin Transl Sci; 2018 Sep; 11(5):523-531. PubMed ID: 29877614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A model with separate hepato-portal compartment ("first-pass" model): fitting to plasma concentration-time profiles in humans.
    Piotrovskij V; Van Peer A
    Pharm Res; 1997 Feb; 14(2):230-7. PubMed ID: 9090715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of the nlmixr R package for population pharmacokinetic modeling: A metformin case study.
    Mak WY; Ooi QX; Cruz CV; Looi I; Yuen KH; Standing JF
    Br J Clin Pharmacol; 2023 Jan; 89(1):330-339. PubMed ID: 35976674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.